Supplementary Figure S1. Combination of GSK2118436 and a c-MET inhibitor, SU11274, did not restore sensitivity to GSK2118436. from EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines

A, Lysates from MV522 cells and GSR cells were evaluated by western blotting to determine total and phosphorylated c-MET levels from the arrays in Fig. 3A. B, MV522 cells and GSR cells were cultured in control (CTL), 0.1 µM GSK2118436 (GSK), or 2 µM SU11274 alone or in combination (GSK + SU). Cell viability was determined using MTT (5 μg/mL) solution by measuring the absorbance at 540 nm in a microplate reader after 72 h for short-term growth inhibition assays. All data are normalized to GSK2118436 or control and are displayed as mean {plus minus} SEM (n = 3, **P < 0.01).